# PTC Therapeutics, Inc.: financial statements, quarterly

PTCT · Nasdaq · CIK 1070081 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ptct.md) · [Financials](/companies/ptct/financials.md) · [Filings](/companies/ptct/filings.md) · [Insiders](/companies/ptct/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ptct/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [307 d](/filings/0001104659-26-017575.md) | [210](/filings/0001070081-25-000019.md) | [187](/filings/0001558370-25-010796.md) | [197](/filings/0001070081-25-000028.md) | [213 d](/filings/0001104659-26-017575.md) | [1,176](/filings/0001070081-26-000012.md) | [179](/filings/0001070081-26-000017.md) | [211](/filings/0001104659-26-120223.md) | [165 d](/filings/0001104659-26-017575.md) | [273](/filings/0001070081-26-000012.md) | [361](/filings/0001070081-26-000017.md) | [358](/filings/0001104659-26-120223.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [121 d](/filings/0001104659-26-017575.md) | [116](/filings/0001070081-25-000019.md) | [132](/filings/0001558370-25-010796.md) | [161](/filings/0001070081-25-000028.md) | [125 d](/filings/0001104659-26-017575.md) | [109](/filings/0001070081-26-000012.md) | [113](/filings/0001070081-26-000017.md) | [100](/filings/0001104659-26-120223.md) | [133 d](/filings/0001104659-26-017575.md) | [101](/filings/0001070081-26-000012.md) | [99.2](/filings/0001070081-26-000017.md) | [105](/filings/0001104659-26-120223.md) |
| Selling, general and administrative | $m | [76.3 d](/filings/0001104659-26-017575.md) | [73.3](/filings/0001070081-25-000019.md) | [69.5](/filings/0001558370-25-010796.md) | [73.5](/filings/0001070081-25-000028.md) | [84.7 d](/filings/0001104659-26-017575.md) | [81.0](/filings/0001070081-26-000012.md) | [85.3](/filings/0001070081-26-000017.md) | [84.0](/filings/0001104659-26-120223.md) | [96.9 d](/filings/0001104659-26-017575.md) | [86.2](/filings/0001070081-26-000012.md) | [80.6](/filings/0001070081-26-000017.md) | [80.1](/filings/0001104659-26-120223.md) |
| Operating income | $m | [5.8 d](/filings/0001104659-26-017575.md) | [(45.5)](/filings/0001070081-25-000019.md) | [(40.2)](/filings/0001558370-25-010796.md) | [(54.5)](/filings/0001070081-25-000028.md) | [(162) d](/filings/0001104659-26-017575.md) | [970](/filings/0001070081-26-000012.md) | [(35.0)](/filings/0001070081-26-000017.md) | [3.0](/filings/0001104659-26-120223.md) | [(71.3) d](/filings/0001104659-26-017575.md) | [45.0](/filings/0001070081-26-000012.md) | [149](/filings/0001070081-26-000017.md) | [25.1](/filings/0001104659-26-120223.md) |
| Income tax | $m | [(1.3) d](/filings/0001104659-26-017575.md) | [6.9](/filings/0001070081-25-000019.md) | [13.4](/filings/0001558370-25-010796.md) | [8.7](/filings/0001070081-25-000028.md) | [(28.8) d](/filings/0001104659-26-017575.md) | [63.3](/filings/0001070081-26-000012.md) | [(6.2)](/filings/0001070081-26-000017.md) | [(39.0)](/filings/0001104659-26-120223.md) | [(4.1) d](/filings/0001104659-26-017575.md) | [0.3](/filings/0001070081-26-000012.md) | [14.0](/filings/0001070081-26-000017.md) | [10.6](/filings/0001104659-26-120223.md) |
| Net income | $m | [(156) d](/filings/0001104659-26-017575.md) | [(91.6)](/filings/0001070081-25-000019.md) | [(99.2)](/filings/0001558370-25-010796.md) | [(107)](/filings/0001070081-25-000028.md) | [(65.9) d](/filings/0001104659-26-017575.md) | [867](/filings/0001070081-26-000012.md) | [(64.8)](/filings/0001070081-26-000017.md) | [15.9](/filings/0001104659-26-120223.md) | [(135) d](/filings/0001104659-26-017575.md) | [(2.8)](/filings/0001070081-26-000012.md) | [83.5](/filings/0001070081-26-000017.md) | [(51.7)](/filings/0001104659-26-120223.md) |
| Diluted EPS | $ per share | not reported | [(1.20)](/filings/0001070081-25-000019.md) | [(1.29)](/filings/0001558370-25-010796.md) | [(1.39)](/filings/0001070081-25-000028.md) | not reported | [10.04](/filings/0001070081-26-000012.md) | [(0.83)](/filings/0001070081-26-000017.md) | [0.20](/filings/0001104659-26-120223.md) | not reported | [(0.03)](/filings/0001070081-26-000012.md) | [0.92](/filings/0001070081-26-000017.md) | [(0.62)](/filings/0001104659-26-120223.md) |
| Basic EPS | $ per share | not reported | [(1.20)](/filings/0001070081-25-000019.md) | [(1.29)](/filings/0001558370-25-010796.md) | [(1.39)](/filings/0001070081-25-000028.md) | not reported | [11.09](/filings/0001070081-26-000012.md) | [(0.83)](/filings/0001070081-26-000017.md) | [0.20](/filings/0001104659-26-120223.md) | not reported | [(0.03)](/filings/0001070081-26-000012.md) | [1.01](/filings/0001070081-26-000017.md) | [(0.62)](/filings/0001104659-26-120223.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [594](/filings/0001070081-25-000012.md) | [548](/filings/0001558370-24-005782.md) | [655](/filings/0001070081-24-000017.md) | [526](/filings/0001070081-24-000023.md) | [780](/filings/0001104659-26-017575.md) | [1,480](/filings/0001070081-25-000019.md) | [1,017](/filings/0001558370-25-010796.md) | [673](/filings/0001070081-25-000028.md) | [985](/filings/0001104659-26-120223.md) | [834](/filings/0001070081-26-000012.md) | [1,050](/filings/0001070081-26-000017.md) | [509](/filings/0001104659-26-120223.md) |
| Current assets | $m | [1,219](/filings/0001070081-25-000012.md) | [1,169](/filings/0001558370-24-005782.md) | [1,358](/filings/0001070081-24-000017.md) | [1,282](/filings/0001070081-24-000023.md) | [1,366](/filings/0001104659-26-017575.md) | [2,316](/filings/0001070081-25-000019.md) | [2,273](/filings/0001558370-25-010796.md) | [2,008](/filings/0001070081-25-000028.md) | [2,274](/filings/0001104659-26-120223.md) | [2,254](/filings/0001070081-26-000012.md) | [2,617](/filings/0001070081-26-000017.md) | [2,538](/filings/0001104659-26-120223.md) |
| Total assets | $m | [1,896](/filings/0001070081-25-000012.md) | [1,790](/filings/0001558370-24-005782.md) | [1,916](/filings/0001070081-24-000017.md) | [1,842](/filings/0001070081-24-000023.md) | [1,705](/filings/0001104659-26-017575.md) | [2,655](/filings/0001070081-25-000019.md) | [2,634](/filings/0001558370-25-010796.md) | [2,644](/filings/0001070081-25-000028.md) | [2,899](/filings/0001104659-26-120223.md) | [2,869](/filings/0001070081-26-000012.md) | [3,250](/filings/0001070081-26-000017.md) | [3,208](/filings/0001104659-26-120223.md) |
| Current liabilities | $m | [603](/filings/0001070081-25-000012.md) | [575](/filings/0001558370-24-005782.md) | [610](/filings/0001070081-24-000017.md) | [611](/filings/0001070081-24-000023.md) | [581](/filings/0001104659-26-017575.md) | [595](/filings/0001070081-25-000019.md) | [628](/filings/0001558370-25-010796.md) | [866](/filings/0001070081-25-000028.md) | [968](/filings/0001104659-26-120223.md) | [924](/filings/0001070081-26-000012.md) | [771](/filings/0001070081-26-000017.md) | [776](/filings/0001104659-26-120223.md) |
| Total liabilities | $m | [2,714](/filings/0001070081-25-000012.md) | [2,684](/filings/0001558370-24-005782.md) | [2,897](/filings/0001070081-24-000017.md) | [2,897](/filings/0001070081-24-000023.md) | [2,803](/filings/0001104659-26-017575.md) | [2,841](/filings/0001070081-25-000019.md) | [2,841](/filings/0001558370-25-010796.md) | [2,799](/filings/0001070081-25-000028.md) | [3,104](/filings/0001104659-26-120223.md) | [3,050](/filings/0001070081-26-000012.md) | [3,416](/filings/0001070081-26-000017.md) | [3,399](/filings/0001104659-26-120223.md) |
| Long-term debt | $m | [284](/filings/0001070081-25-000012.md) | [285](/filings/0001558370-24-005782.md) | [285](/filings/0001070081-24-000017.md) | [285](/filings/0001070081-24-000023.md) | [285](/filings/0001104659-26-017575.md) | [286](/filings/0001070081-25-000019.md) | [286](/filings/0001558370-25-010796.md) | not reported | not reported | not reported | [536](/filings/0001070081-26-000017.md) | [536](/filings/0001104659-26-120223.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [286](/filings/0001070081-25-000028.md) | [287](/filings/0001104659-26-120223.md) | [287](/filings/0001070081-26-000012.md) | [55.5](/filings/0001070081-26-000017.md) | not reported |
| Shareholders' equity | $m | [(819)](/filings/0001104659-26-017575.md) | [(894)](/filings/0001558370-25-010796.md) | [(980)](/filings/0001070081-25-000028.md) | [(1,054)](/filings/0001070081-25-000028.md) | [(1,098)](/filings/0001104659-26-120223.md) | [(186)](/filings/0001070081-26-000017.md) | [(207)](/filings/0001104659-26-120223.md) | [(156)](/filings/0001104659-26-120223.md) | [(205)](/filings/0001104659-26-120223.md) | [(180)](/filings/0001070081-26-000017.md) | [(165)](/filings/0001104659-26-120223.md) | [(191)](/filings/0001104659-26-120223.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(100) d](/filings/0001104659-26-017575.md) | [70.8](/filings/0001070081-25-000019.md) | [(71.5) d](/filings/0001558370-25-010796.md) | [(77.0) d](/filings/0001070081-25-000028.md) | [(30.0) d](/filings/0001104659-26-017575.md) | [870](/filings/0001070081-26-000012.md) | [(58.3) d](/filings/0001070081-26-000017.md) | [(66.3) d](/filings/0001104659-26-120223.md) | [(34.3) d](/filings/0001104659-26-017575.md) | [(59.0)](/filings/0001070081-26-000012.md) | [129 d](/filings/0001070081-26-000017.md) | [(25.3) d](/filings/0001104659-26-120223.md) |
| Capital expenditure | $m | [5.6 d](/filings/0001104659-26-017575.md) | [9.6](/filings/0001070081-25-000019.md) | [(7.4) d](/filings/0001558370-25-010796.md) | [0.5 d](/filings/0001070081-25-000028.md) | [3.8 d](/filings/0001104659-26-017575.md) | [1.7](/filings/0001070081-26-000012.md) | [1.2 d](/filings/0001070081-26-000017.md) | [3.5 d](/filings/0001104659-26-120223.md) | [2.4 d](/filings/0001104659-26-017575.md) | [1.2](/filings/0001070081-26-000012.md) | [2.2 d](/filings/0001070081-26-000017.md) | [2.7 d](/filings/0001104659-26-120223.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [73.7](/filings/0001558370-24-005782.md) | [74.7](/filings/0001070081-24-000017.md) | [75.4](/filings/0001070081-24-000023.md) | [76.5](/filings/0001070081-25-000019.md) | [76.7](/filings/0001558370-25-010796.md) | [76.9](/filings/0001070081-25-000028.md) | [86.4](/filings/0001070081-26-000012.md) | [78.2](/filings/0001070081-26-000017.md) | [87.1](/filings/0001104659-26-120223.md) | [82.5](/filings/0001070081-26-000012.md) | [92.0](/filings/0001070081-26-000017.md) | [83.5](/filings/0001104659-26-120223.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 83,544,284 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001104659-26-120223.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:45 ET. No prices; not investment advice.